Skip to content

Fortress Biotech, Inc.

FBIO· NasdaqCore metricsCIK 1429260

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · -1.00%
Market cap
$66.65M
33.49M shares
Filings
888
$19.16M
Q3 2026+9.7% FY25 yoy
-$5.85M
Q3 2026N/M FY25 yoy
-$7.19M
Q3 2026N/M FY25 yoy
$138.29M
Q3 2026derivedN/M FY24 yoy
-$0.23
Q3 2026N/M FY25 yoy
$152.19M
Q3 2026+38.6% FY25 yoy
$66.65M
0.7×
1.0×
0.4×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$1.9925.75%$0.69past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$63.26MFY 2025
$84.51M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$63,262,000reported
FY 20242024-12-31$57,675,000reported
FY 20232023-12-31$84,513,000reported
FY 20222022-12-31$75,743,000reported
FY 20212021-12-31$68,791,000reported
FY 20202020-12-31$45,599,000reported
FY 20192019-12-31$36,629,000reported
FY 20182018-12-31$26,882,000reported
FY 20172017-12-31$17,245,000 revisedreported
FY 20162016-12-31$16,480,000reported
FY 20152015-12-31$863,000reported
FY 20142014-12-31$0reported

Capital returns

Dividends and buybacks · FY2019 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025$664.00K—$664.00K—31.36M sh+12.4%—
FY2024$694.00K—$694.00K—27.91M sh+84.9%—
FY2023$736.00K—$736.00K—15.09M sh+104.9%—
FY2022$749.00K—$749.00K—7.37M sh−92.7%—
FY2021$749.00K—$749.00K—101.44M sh+6.9%—

Segments

Revenue by Segments, FY2019 to FY2025FY2019Dermatology Products Sales · FY2019 · $34.92MPharmaceutical and Biotechnology Product Development · FY2019 · $1.71MFY2020Dermatology Products Sales · FY2020 · $44.53MPharmaceutical and Biotechnology Product Development · FY2020 · $1.07MFY2021Dermatology Products Sales · FY2021 · $63.13MPharmaceutical and Biotechnology Product Development · FY2021 · $5.66MFY2022Dermatology Products Sales · FY2022 · $73.67MPharmaceutical and Biotechnology Product Development · FY2022 · $2.07MFY2023Journey · FY2023 · $79.18MCheckpoint Merger · FY2023 · $103.00KDermatology Products Sales · FY2023 · $79.18MFortress · FY2023 · $5.23MPharmaceutical and Biotechnology Product Development · FY2023 · $5.33MFY2024Journey · FY2024 · $56.13MCheckpoint Merger · FY2024 · $41.00KFortress · FY2024 · $1.50MFY2025Journey · FY2025 · $61.86MAvenue · FY2025 · $1.40M
LineFY2025ShareChange
Journey$61.86M98%+10.2%
Avenue$1.40M2.2%—
Checkpoint Merger———
Dermatology Products Sales———
Fortress———
Pharmaceutical and Biotechnology Product Development———
Total$63.26M

From the 10-K filed Mar 31, 2026FBIO

Pharmaceutical preparations

Fortress Biotech, Inc. is the 119th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Fortress Biotech, Inc. · CIK 1429260 · Engraved from SEC EDGAR